Barclays raised the firm’s price target on Boston Scientific (BSX) to $118 from $111 and keeps an Overweight rating on the shares. The firm ...

Q4 2024 Management View CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price target ...

Feb 5 (Reuters) - Medical device maker Boston Scientific (BSX.N), opens new tab forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Q4 2024 Earnings Call Transcript February 5, 2025 Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is ...

Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...

For the current quarter ending in March, Boston Scientific expects its per-share earnings to range from 66 cents to 68 cents. The company expects full-year earnings in the range of $2.80 to $2.87 per ...

The most recent trading session ended with Boston Scientific (BSX) standing at $91.29, reflecting a +0.66% shift from the previouse trading day's closing. The stock exceeded the S&P 500 ...

Boston Scientific (NYSE:BSX) announced on Wednesday the acquisition of the ~74% stake in Bolt Medical that the medical devices company does not already own. BSX shares were trading +2.07% pre ...